Patient P-02051
Therapy response
Stable
Tolerance
Stable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
59%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 GI symptom burden −26% vs expected — Dietary Support Protocol NP-02
- Day 64 Tolerance state changed — Unstable → Improving
- Day 74 GI-04 recommended — GI Support Protocol GI-04
- Day 74 SC-12 recommended — Supportive Compound SC-12
- Day 75 Patient accepted — Started GI-04 in the companion
- Day 75 Patient declined — Not now
- Day 83 GI symptom burden −31% vs expected — GI Support Protocol GI-04
- Day 85 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 88 ME-01 recommended — Monitoring Escalation ME-01
- Day 89 Tolerance state changed — Unstable → Improving
- Day 89 Patient accepted — Started ME-01 in the companion
- Day 92 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 85.
Primary contributors, last 14 days
- GI instability-10
- Inflammatory activity-7
- Treatment adherence+5
What helped?
- Dietary Support Protocol NP-02Day 47Result: symptom burden −26%
- GI Support Protocol GI-04Day 74Result: symptom burden −31%
- Supportive Compound SC-12Day 74Declined by patient
- Monitoring Escalation ME-01Day 88Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
54%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 69% showed improvement
- median effect visible after 6 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable49 min
stable · -1.0 vs previous 14 d
Sleep duration
Wearable6.5 h
stable · +0.1 vs previous 14 d
Energy level
Daily log3.8/10
stable · +0.1 vs previous 14 d
Steps
Wearable6,045
stable · -131 vs previous 14 d
GI burden
Companion40.3/100
worsening · +2.3 vs previous 14 d
Adherence
Companion53.3 %
worsening · -2.7 vs previous 14 d
Sleep quality
Wearable52/100
stable · +0.0 vs previous 14 d
Glucose, CGM daily mean
CGM146 mg/dL
stable · +0.1 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 41 from the failing basin, 47 from restoration.
Good elements to keep
- GI Support Protocol GI-04intervention · steering +42.2
- Dietary Support Protocol NP-02intervention · steering +25.3
- Protein (supports)perturbation · steering +9.5
- Butyrate producers intacthidden · steering +7.5
- Proteinsupporter · GI -5 next day
Main detractors to watch
- Poor metabolizerhidden · steering -12.7
- FUT2 non-secretorhidden · steering -10.6
- Caffeineperturbation · steering -9.6
- IL6 high-expression varianthidden · steering -7.3
- Caffeinedetractor · GI +5.5 next day
- Ultra-processed fooddetractor · GI +4.8 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Caffeine+5.5detractor · 95%
- Protein-5supporter · 95%
- Ultra-processed food+4.8detractor · 95%
- Histamine load+4.4detractor · 95%
- Alcohol+3.7detractor · 83%
- Insoluble fibre-1no signal · 21%
- Dietary fat load+0.8no signal · 15%
- Simple carbohydrates+0.7no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 48
- Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 46
- Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 3.2 · butyrate capacity 47/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 57 ms
- Sleep
- 6.4 h
- Steps
- 5,618
- Resting HR
- 64 bpm
Daily log: GI score 40, nutritional resilience 46, adherence 53.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02504 | 52% | S14 | GI-04 | improved | 52 |
| P-02176 | 49% | S14 | GI-04 | improved | 52 |
| P-02328 | 49% | S14 | GI-04 | improved | 42 |
| P-02255 | 48% | S14 | GI-04 | improved | 43 |
| P-02323 | 45% | S14 | GI-04 | improved | 27 |
| P-02103 | 44% | S14 | GI-04 | improved | 46 |
| P-02108 | 44% | S14 | GI-04 | improved | 43 |
| P-02002 | 43% | S14 | GI-04 | improved | 47 |
| P-02106 | 43% | S14 | GI-04 | improved | 44 |
| P-02310 | 43% | S14 | GI-04 | improved | 35 |
| P-02401 | 43% | S14 | GI-04 | improved | 49 |
| P-02674 | 43% | S02 | NP-02 | improved | 48 |